JAK2 and myeloproliferative neoplasm: In another report, PLEK2 was found to be an effector of the JAK2/STAT5 pathway and an important regulator in the pathogenesis of JAK2V617F-induced myeloproliferative neoplasms, suggesting that PLEK2 is a feasible therapeutic target of myeloproliferative neoplasms [21].